Next Article in Journal
Next Article in Special Issue
Previous Article in Journal
Med. Sci. 2013, 1(1), 37-48; doi:10.3390/medsci1010037
Review

Cellular Immunotherapy: Using Alloreactivity to Induce Anti-Leukemic Responses without Prolonged Persistence of Donor Cells

1,†,* , 2,†
 and 2
Received: 29 September 2013; in revised form: 21 October 2013 / Accepted: 11 November 2013 / Published: 15 November 2013
(This article belongs to the Special Issue Recent Advances in Cellular Immunotherapy)
View Full-Text   |   Download PDF [989 KB, uploaded 15 November 2013]
Abstract: A goal of cancer immunologists is to harness cellular immune responses to achieve anti-cancer responses. One of the strongest activating stimuli for the immune system is the encounter with cells expressing allogeneic HLA molecules. While alloreactive responses can negatively impact of the outcome of hematopoietic stem cell transplant because of graft-versus-host disease (GVHD), these same responses can have anti-leukemic effects. Donor lymphocyte infusions have been used in an attempt to harness alloreactive responses to achieve anti-leukemic responses. Because this protocol is usually carried out in the absence of recipient anti-donor responses, this protocol often induces GVHD as well as anti-leukemic responses. A recent study indicated the infusion of large number of haploidentical donor cells (1–2 × 108 CD3+ cells/kg) into patients with refractory hematological malignancies (100 cGy total body irradiation) resulted in 14 (7 major) responses/26 patients. A rapidly developing cytokine storm was observed, while no persisting donor cells could be detected at two weeks after infusion eliminating the possibility of GVHD. Characterization of the effector mechanisms responsible for the anti-leukemic responses in this protocol, should guide new approaches for achieving enhanced anti-leukemic responses using this protocol.
Keywords: alloreactivity; haploidentical; cellular immunotherapy; donor cell infusion alloreactivity; haploidentical; cellular immunotherapy; donor cell infusion
This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Export to BibTeX |
EndNote


MDPI and ACS Style

Fast, L.D.; Reagan, J.; Quesenberry, P. Cellular Immunotherapy: Using Alloreactivity to Induce Anti-Leukemic Responses without Prolonged Persistence of Donor Cells. Med. Sci. 2013, 1, 37-48.

AMA Style

Fast LD, Reagan J, Quesenberry P. Cellular Immunotherapy: Using Alloreactivity to Induce Anti-Leukemic Responses without Prolonged Persistence of Donor Cells. Medical Sciences. 2013; 1(1):37-48.

Chicago/Turabian Style

Fast, Loren D.; Reagan, John; Quesenberry, Peter. 2013. "Cellular Immunotherapy: Using Alloreactivity to Induce Anti-Leukemic Responses without Prolonged Persistence of Donor Cells." Med. Sci. 1, no. 1: 37-48.

Med. Sci. EISSN 2076-3271 Published by MDPI AG, Basel, Switzerland RSS E-Mail Table of Contents Alert